Home
overview

VIRTUAL CONFERENCE: ONLINE ACCESS ONLY
Announcement: Due to ongoing concerns over COVID-19 we have now made this conference a virtual event. All speakers, attendees and sponsors will be able to access the full conference and its materials and will be able to log on remotely via the internet. Please contact a member of the SMi Team for more information customerservices@smi-online.co.uk 

The SMi Group is delighted to announce its 20th Annual Pain Therapeutics conference held on 11 and 12 May 2020 which is a VIRTUAL CONFERENCE: ONLINE ACCESS ONLY

The Global Pain Therapeutics Market was valued at $11.26 Million in 2018 and is projected to reach $15.87 Million by 2026, growing at a CAGR of 4.40 % from 2019 to 2026. Improving pain management continues to be a priory as pain-derived disabilities such as osteoarthritis, back pain, migraines and cancer are leading cause of disability worldwide. Yet, pain treatment remains the biggest clinical burden of the age as a result of lack of efficacy, increasing side effects and the opioid crisis that is now entering Europe following its epidemic in the USA.

The 20th Annual Conference will overview the current state of pain treatment highlighting clinical success to date as well as evaluating the potential of drug candidates in the pipelines.

Join Europe's leading Pain Therapeutics Conference which will explore the cutting-edge research of novel therapeutics in the pipeline of leading pharmaceutical companies and research institutions. Discuss solutions for the challenges of understanding pain as a heterogenous disease and the diverse treatment approaches it requires.

• Network with leading pharmaceutical companies and academic researchers of the pain community including GSK, Centrexion, Grunenthal Group, Mundipharma Research Limited, UCL, Janssen, University of Edinburgh and many more!

• Rethink pain research by exploring novel biomarkers, sex differences in nociception, pain clinical trial design and novel targets

• Learn about the struggles of opioid-based treatments and explore the current stages of clinical research with non-opioid targets such as; cannabinoid receptor 2, nociception/orphanin FQ peptide (NOP) receptor, ENKephalinase and NGF receptors

• Improve your understanding of neuro-immune interactions and their role in pain pathology, a promising new angle of pain research
 

Chief Executive Officers, Chief Scientific Officers, Chief Medical Officers, Managing Directors, CEO, Head of Departments, Principal Research Scientists, Clinical Lead, Clinical Operations in the following fields:

  • Pain and Migraine
  • Pain Innovation R&D
  • Neuroscience
  • CNS
  • Neuropathic Pain
  • Analgesic clinical development
  • Anesthesia and Pain Management
  • CNS clinical trials
  • Translational science
  • Drug development
  • Discovery Medicine
  • Exploratory development
  • Clinical and pharmaceutical operations
  • Medical Affairs

Adynxx Inc.; Alterion Consulting; Asahi Kasei Pharma; Asahi Kasei Pharma Corporation; AstraZeneca; AstraZeneca R&D Biopharmaceuticals; Bayer AG; BRAINCURES LTD; Centre for Human Drug Research; Centrexion Therapeutics Corp; Clexio Biosciences; Domain Therapeutics ; Eli Lilly and Company; Ensysce Biosciences Inc.; Grunenthal; Grünenthal GmbH; Grunenthal Group; Grunenthal Ltd; GSK; Janssen Pharmaceutica N.V.; Levicept; Lotus Clinical Research, LLC; MD Biosciences; Medherant Limited; Metys Pharmaceuticals Ltd; Pfizer Ltd; Pharmaleads; Reckitt Benckiser; Tools4patient; Travecta Therapeutics; UMR 1107 INSERM/UCA NEURO-DOL; Vertex Pharmaceuticals; ViroMed ;

Conference programme

13:00 Chairs' Opening Remarks

Kerrie Brady

Kerrie Brady, Chief Business Officer, Centrexion Therapeutics Corp
View Bio

Michael Scherz

Michael Scherz, Founder & CEO, Metys Pharmaceuticals Ltd
View Bio

13:10 Facilitating Pain Research via Biomarker Discovery

Richard Malamut

Richard Malamut, Chief Medical Officer and SVP R&D, Collegium Pharma
View Bio

•Evaluating the role of biomarkers in pain research
•Identifying biomarkers – where are we now?
•Establishing biomarkers in patient populations
•Highlighting the importance of biomarker discovery and its contribution to early stage studies on pain

13:40 Neurotrophins in pain models

Cristina Cosi

Cristina Cosi, Former Senior Scientist, Pharmacology, CNS Innovation Unit, Pierre Fabre Research Institute
View Bio

•Pain models for pre-clinical research
•Focus on BDNF, NGF, TrkB, TrkA systems
•Biomarkers, target validation and engagement
•Considering translatability of pain across species

14:10 Sex Differences in Pain Mechanisms

Carole Torsney

Carole Torsney, Senior Lecturer, University of Edinburgh
View Bio

•Highlight evidence for sex differences in neuro-immune interactions
•Highlight evidence for sex differences in PNS and CNS plasticity
•Discuss sex differences in the temporal relay of pain signals by nociceptors
•Address the need for preclinical research on both sexes to improve translation

14:40 Pain clinical trials - myths and momentum

Kerrie Brady

Kerrie Brady, Chief Business Officer, Centrexion Therapeutics Corp
View Bio

•Examining pain clinical trial myths
•Raising patient awareness to improve clinical trials
•Consideration of new clinical trial design approaches

15:10 Afternoon Break

15:40 Panel Discussion: Novel drug targets on the horizon

•Discussing the diversity of targets that have been explored for the treatment of neuropathic pain
•Evaluating the current situation and status of targets in clinic
•What are the new targets on the horizon that should be fully explored?
•Starting with a target ending with a drug – challenges encountered

Richard Malamut

Richard Malamut, Chief Medical Officer and SVP R&D, Collegium Pharma
View Bio

Sandrine Geranton

Sandrine Geranton, Associate Professor, Department of Cell and Developmental Biology, UCL
View Bio

Jennifer Laird

Jennifer Laird, Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company
View Bio

16:20 Selecting targets for a novel pain therapy: Expanding the druggable space

Jennifer Laird

Jennifer Laird, Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company
View Bio

•Translatability of preclinical evidence is debated in the pain field, but are there exceptions that prove (or disprove) the rule?
•Alternatively, can we take an opportunistic approach and focus on targets with clinical evidence provided by serendipity?
•This presentation will address those questions and also discuss how novel modalities like oligonucleotides or gene therapy can change the types of targets we focus our efforts on
 

16:50 FKBP51 and the stress axis: novel targets for the control of chronic pain

Sandrine Geranton

Sandrine Geranton, Associate Professor, Department of Cell and Developmental Biology, UCL
View Bio

•Stress and chronic pain are known to exacerbate each
other but the underlying mechanisms remain elusive
•FKBP51 is a well-known regulator of the stress axis and its inhibition improves anxiety-like behaviour in mouse models
•We have shown that FKBP51 is a crucial driver of persistent pain states
•Targeting the stress axis overall is likely to reduce the pain experience

17:20 Evaluation of the Selective Cannabinoid 2 Receptor Agonist CNTX-6016 for the Treatment of Neurophatic pain

James Campbell

James Campbell, Chief Scientific Officer , Centrexion Therapeutics Corp

•Introducing CB2 receptors as targets and their implication in pain
Presenting recent result from clinical trials of CNTX-6016
•Implications for treatment of chronic neuropathic pain, such as diabetic neuropathic pain and chemotherapy induced neuropathy

17:50 Chairs' Closing Remarks

Kerrie Brady

Kerrie Brady, Chief Business Officer, Centrexion Therapeutics Corp
View Bio

Michael Scherz

Michael Scherz, Founder & CEO, Metys Pharmaceuticals Ltd
View Bio

13:00 Chairs' Opening Remarks

Kerrie Brady

Kerrie Brady, Chief Business Officer, Centrexion Therapeutics Corp
View Bio

Michael Scherz

Michael Scherz, Founder & CEO, Metys Pharmaceuticals Ltd
View Bio

13:10 The impact of chronic pain – the patient’s perspective

Joop van Griensven

Joop van Griensven, President , Pain Alliance Europe (PAE)
View Bio

•Understanding the effects of chronic pain on the quality of life and on society
•Observing health aspects of chronic pain
•Promoting awareness and helping patient cope with chronic pain

13:40 Revolutionising pain R&D by developing Precision Analgesics

Mark  J Field

Mark J Field, Owner/Founder, Analgesic Innovation
View Bio

• Overviewing the impact of pain and its huge global burden with up to 1 in 4 of us affected
• Discussing why pain is an area with some of the LOWEST R&D success rates
• Learning what factors are hindering analgesic development
• Highlighting how developing precision analgesics can radically improve probability of success
 

14:10 Emphasising Disease Understanding to deliver effective pain treatments. Exploring NOP receptor pharmacology as an exciting opportunity to treat neuronal hypersensitivity driven pain disorders

Paul Ratcliffe

Paul Ratcliffe, Vice President, Setup Innovation Hubs , Grunenthal Group
View Bio

•Grunenthal’s approach to tackle the underlying pathophysiologies of pain

•Targeting the nociception/orphanin FQ peptide (NOP) receptor; a journey navigating between the pre-clinic and clinical environment

14:40 Novel botulinum-based constructs for the long-term control of persistent pain states in mice

Stephen Hunt

Stephen Hunt, Professor, UCL
View Bio

•The evidence for opiate control of chronic pain states is poor
•This is related to the development of tolerance, increased pain sensitivity and therefore escalating dose of opiate drug that can lead to addiction.
•A novel conjugation of dermorphin to the silencing domain of botulinum toxin, that is safe to produce under laboratory conditions, results in long term amelioration of persistent pain states in mice following one intrathecal injection.
•The analgesia lasts for over three months without killing neurons or obvious toxic events

15:10 Afternoon Break

15:40 Fremanezumab Clinical Trials: Results in a Broad Range of Migraine Patients, Including Those with Difficult-to Treat Migraine

Joshua M. Cohen

Joshua M. Cohen, Global Medical Lead for Migraine & Headache, Teva Pharmaceuticals
View Bio

  • Overall Trial Results in Episodic and Chronic Migraine with Quarterly and Monthly Dosing
  • Patients with Comorbid Depression
  • Patients with Medication Overuse
  • Patients with Prior Treatment Failures
  • 16:20 Fibromyalgia and migraine: a potential common ground. Challenges and limitations of available treatments for people suffering from both conditions'

    Domenico Merante

    Domenico Merante, VP Clinical Development, Independent

  • How do patients respond to available treatments?
  • Considering aspects of tolerability and side effects of existing treatments
  • Examining efficacy limitations of current treatments
  • Common clinical ground of fibromyalgia and migraine and potential for novel treatments targeting both conditions
     
  • 16:40 Recent Progress of PL37 – a Dual ENKephalinase Inhibitor for migraine treatment

    Tanja Ouimet

    Tanja Ouimet, Head of Clinical Operations, Pharmaleads
    View Bio

    •Introducing DENKI and PL37 MoA
    •Presenting recent preclinical pharmacology results on the potential of PL37 in migraine treatment
    •Assessing the potential of PL37 and future studies required

    17:10 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Carole Torsney

    Carole Torsney

    Senior Lecturer, University of Edinburgh
    Cristina Cosi

    Cristina Cosi

    Former Senior Scientist, Pharmacology, CNS Innovation Unit, Pierre Fabre Research Institute
    Domenico Merante

    Domenico Merante

    VP Clinical Development, Independent
    Edward Emery

    Edward Emery

    Investigator, GSK
    James Campbell

    James Campbell

    Chief Scientific Officer , Centrexion Therapeutics Corp
    Jennifer Laird

    Jennifer Laird

    Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company
    Joop van Griensven

    Joop van Griensven

    President , Pain Alliance Europe (PAE)
    Kerrie Brady

    Kerrie Brady

    Chief Business Officer, Centrexion Therapeutics Corp
    Mark  J Field

    Mark J Field

    Owner/Founder, Analgesic Innovation
    Paul Ratcliffe

    Paul Ratcliffe

    Vice President, Setup Innovation Hubs , Grunenthal Group
    Richard Malamut

    Richard Malamut

    Chief Medical Officer and SVP R&D, Collegium Pharma
    Sandrine Geranton

    Sandrine Geranton

    Associate Professor, Department of Cell and Developmental Biology, UCL
    Stephen Hunt

    Stephen Hunt

    Professor, UCL
    Tanja Ouimet

    Tanja Ouimet

    Head of Clinical Operations, Pharmaleads
    Theo Meert

    Theo Meert

    Head of R&D Global Government Grant Office, Janssen Pharmaceutica N.V.
    Zahid Ali

    Zahid Ali

    Head Clinical Pharmacology Translational Sciences, Mundipharma research Ltd

    Carole Torsney

    Senior Lecturer, University of Edinburgh
    Carole Torsney

    Carole Torsney is a Senior Lecturer in the Centre for Discovery Brain Sciences at the University of Edinburgh. Carole Torsney received her PhD from University College London as part of the Wellcome Trust 4 year PhD programme in Neuroscience with Professor Maria Fitzgerald. Following postdoctoral training at Columbia University, New York with Professor Amy MacDermott she was then awarded a Caledonian Research Foundation Fellowship, then Senior Academic Fellowship followed by a Lectureship at the University of Edinburgh. She studies pain pathophysiology primarily using electrophysiological approaches and is a member of the Edinburgh Translational Pain Research Group.

    Cristina Cosi

    Former Senior Scientist, Pharmacology, CNS Innovation Unit, Pierre Fabre Research Institute
    Cristina Cosi

    Biologist and pharmacologist , biochemist by training , with a Master in Science from the University of Florence , and a PhD in Pharmacology from the University of Toulouse, 1997, Cristina Cosi has an extensive working experience in the Neuroscience research field, mostly in industry at Pierre Fabre, France, but also in academic environments, in Italy , University of Florence and Verona, and US, NIH. She has focused her career on the understanding of neurodegenerative processes and mechanisms of neuronal plasticity in order to find medications that might be beneficial against neurodegenerative and neurodevelopmental diseases and pain.

    Domenico Merante

    VP Clinical Development, Independent
    Domenico Merante

    Edward Emery

    Investigator, GSK
    Edward Emery

    Ed started his career in pain research in the lab of Prof. Peter McNaughton at the University of Cambridge in 2008, investigating the role of HCN2 ion channels in chronic pain. Ed went on to complete postdoctoral positions with Prof. Fiona Gribble at the Institute of Metabolic Science, in Cambridge and with Prof. John Wood at University College London, where his work was focussed on understanding the role of voltage-gated sodium channels in nociception, as well as developing imaging techniques to study sensory neuron physiology, in vivo. In April 2019, Ed moved to GSK to help suport their pain research strategy.

    James Campbell

    Chief Scientific Officer , Centrexion Therapeutics Corp
    James Campbell

    Jennifer Laird

    Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company
    Jennifer Laird

    Jennifer Laird, Ph.D., D.Sc. is Vice-President, Search & Evaluation Pain & Neurodegeneration at Eli Lilly and Company, based at Lilly’s European Headquarters, London, UK. Her role, along with her team, is to complement Lilly’s internal R&D efforts by in-licensing or acquiring novel therapeutics and technologies for the Lilly portfolio, and to advance molecules through drug discovery and development in collaboration with external partners globally. Prior to joining Lilly in 2012, Dr. Laird held leadership roles in Translational Science, Project Management and Pharmacology at AstraZeneca, in academia and Merck, primarily focused on the discovery and development of novel analgesics. Dr. Laird served as an Editorial Board member of Pain, Neuropharmacology and European Journal of Pain and held an honorary appointment as Professor of Pharmacology at McGill University, Canada. She received doctorates from the University of Bristol, UK and University of Alicante, Spain, and post-doctoral training at NIH, USA.

    Joop van Griensven

    President , Pain Alliance Europe (PAE)
    Joop van Griensven

    Joop was born in Tilburg, in the Netherlands, is married, has a son, a daughter and a grandchild.

    Because of physical problems (fibromyalgia) Joop lost his job at the age of 35. Since 2008 he has been involved in the European Network of Fibromyalgia Associations, as treasurer. Since 2011 he is the President of Pain Alliance Europe (PAE), a European umbrella alliance of national associations involved with chronic pain.

    He is member of the patient advisory board of the Dutch Medicines Evaluation Board (CBG/MEB) and act as a patient expert on pain and fibromyalgia for the European Medicine Agency (EMA).


     

    Joshua M. Cohen

    Global Medical Lead for Migraine & Headache, Teva Pharmaceuticals
    Joshua M. Cohen

    Joshua M. Cohen, MD, MPH, FAHS is Global Medical Lead for Migraine & Headache at Teva Pharmaceuticals. He completed Board certification in Neurology and Headache Medicine. He was chosen as a Super Doctors® 2013 and 2014 New York Rising Stars™ and was selected as a Castle Connolly America’s Top Doctors™ in 2015. Dr. Cohen completed undergraduate training at Harvard University, medical school at the New York University School of Medicine, and neurology residency at Columbia University's Neurological Institute. At the Columbia Mailman School of Public Health, he received his Masters of Public Health. He completed headache fellowship at The Headache Institute.
     

    Kerrie Brady

    Chief Business Officer, Centrexion Therapeutics Corp
    Kerrie Brady

    Kerrie Brady is a founder and chief business officer of Centrexion Therapeutics. Kerrie’s career includes 30 years of experience as an international pharmaceutical executive working in both big pharma and biotech companies. Prior to joining Centrexion, Kerrie was the chief operations officer for Vallinex Inc., a company she founded as a spin out from Arcion Therapeutics, Inc., a biotech company developing topical products for the treatment of neuropathic pain. Kerrie was also the co-founder and chief operations officer for Arcion Therapeutics Inc. Previously, she was the founder, president and chief executive officer of Traxion Therapeutics, Inc., a biotech company focused on the development of new drugs to treat intractable pain. Prior to starting on the entrepreneurial path Kerrie’s experience spanned business development (KMG Japan, Entremed, Intracel), business operations (CMC for Biopharmaceutical Research), marketing and regulatory affairs (Rhone Poulenc) Kerrie holds a BPharm from Victorian College of Pharmacy, an MBA from the University of Melbourne and an M.S. in biopharmaceuticals from the University of New South Wales. In 2016, Kerrie was named to the PharmaVOICE100 Most Inspiring People for her contributions to the life-sciences industry.

    Mark J Field

    Owner/Founder, Analgesic Innovation
    Mark  J Field

    Mark is a senior executive with over 30 years’ experience in pharmaceutical industry spanning both preclinical research & clinical development. Currently owner of Analgesic Innovation with the mission to create awareness & new therapeutic solutions for Chronic Pain Patients (AnalgesicInnovation.com)

    Focus has been on helping patients with chronic pain by identifying novel analgesics during a career working at large and mid-size companies including: MSD, Parke-Davis, Pfizer, UCB and Grünenthal. Latest Industry role was Head Pain R&D at Grünenthal: responsible for people (~200) budget (~€150M) to drive projects from research (Target ID) to clinical Phase III.

    Mark has been associated with over 35 compounds progressing into clinical development and led the research that identified the utility in pain and the Mechanism of Action for Gabapentin (Neurontin®) and Pregabalin (Lyrica®). Lyrica having 2017 revenues of over $5 Billion.

    Mark’s research is documented in over 100 full-length manuscripts, abstracts and patents with ~4500 citations.

    Mark is a Fellow of the Royal Society of Biology (FRSB), a Fellow of the Institute of Science & Technology (FIScT) and a Visiting lecturer at King’s College London.
     

    Michael Scherz

    Founder & CEO, Metys Pharmaceuticals Ltd
    Michael Scherz

    Michael Scherz manages drug development and drug discovery activities at Metys Pharmaceuticals, and is spearheading the company’s search for Series A investors. He is responsible for managing the corporate budget, and
    for the selection of suitable consultants for Metys’ drug development and drug discovery activities. He is
    responsible for Metys’ development plans for MP-101, a newly-patented orally-active Phase II-ready small molecule intended for the treatment and prevention of neuropathic pain, in a first clinical trial for the prevention of chemotherapy-induced symptoms of peripheral neuropathy. Since creating Metys Pharmaceuticals, Scherz has worked to share Metys’ vision and strategy with its investors and consultants.
    Michael Scherz graduated in 1989 from the University of Oregon with a PhD in synthetic and medicinal
    chemistry. Previously, he served as vice president and life cycle leader at Actelion Pharmaceuticals, where he was responsible for the multi-functional development teams entrusted with the Phase I to Phase III clinical development of several novel therapeutic agents. His focus on innovation, team performance, and clear communication, led to the discovery of novel candidate therapeutic agents: urotensin-II antagonists, sphingosine-1-phosphate agonists, and novel calcium channel blockers; and significant advancements of the Phase I to pre-Phase III clinical projects he led. Prior to Actelion, Scherz was section head of cardiac research at Procter & Gamble Pharmaceuticals in Cincinnati, Ohio, USA; and post-doc at Hoffman-La Roche AG in Basel, Switzerland.
     

    Paul Ratcliffe

    Vice President, Setup Innovation Hubs , Grunenthal Group
    Paul Ratcliffe

    A scientist and entrepreneurial leader with extensive expertise in drug discovery and early development. Recognised as an innovative and visionary mentor with strong motivational and change management skills, able to nurture teams to ensure successful project delivery. A track record of leading international projects in both large and mid-sized Pharma and adept at developing global collaborative networks and partnerships with Biotechs, CROs and Academic institutes. A member of the R&D leadership Team he is currently responsible for the implementation of Grünenthal’s Innovation Hub strategy within Europe and China, tasked with driving research and early clinical projects to Proof of Concept.
     

    Richard Malamut

    Chief Medical Officer and SVP R&D, Collegium Pharma
    Richard Malamut

    Dr Malamut is currently Chief Medical Officer and Executive Vice President at Collegium Pharmaceuticals which is committed to be the leader in responsible pain management. He has also served as Chief Medical Officer for Braeburn Pharmaceuticals, Inc. where he was responsible for the company’s medical affairs, non-clinical and clinical development, clinical operations, research and development quality assurance, and pharmacovigilance functions. Prior to that, Dr. Malamut had similar responsibilities as Chief Medical Officer at Avanir Pharmaceuticals and was Senior Vice President of Global Clinical Development at Teva Pharmaceutical Industries Ltd where he was responsible for Pain, Neuropsychiatry, Oncology, and New Therapeutic Entities. His experience also includes roles of increasing responsibility focusing on early clinical development and translational medicine in Neurology, Psychiatry and Analgesia at Bristol-Myers Squibb and AstraZeneca.

    Dr. Malamut earned his medical degree from Hahnemann University in Philadelphia and completed both a residency in Neurology and a fellowship in Neuromuscular disease. He worked as a board-certified academic and clinical neurologist for 17 years and has more than 50 publications in the fields of pain medicine, neuromuscular disease, autonomic disease, and neurodegenerative disease.
     

    Sandrine Geranton

    Associate Professor, Department of Cell and Developmental Biology, UCL
    Sandrine Geranton

    Sandrine Géranton is Associate Professor in molecular neuroscience in the department of Cell and Developmental Biology at University College London. Sandrine studied organic chemistry and biochemistry at the “Ecole Nationale Supérieure de Chimie de Montpellier” in France. After an MSc in biotechnology, she joined UCL where she obtained a PhD in Pharmacology. She went on learning about pain mechanisms as a post-doctoral researcher with the London Pain Consortium at UCL, where she is now Associate Professor. Sandrine has always been keen on applying her multidisciplinary background to further her understanding of the molecular biology of chronic pain and she has been at the forefront of the investigation of the role of epigenetic mechanisms in this context.

    Stephen Hunt

    Professor, UCL
    Stephen Hunt

    Professor Stephen Hunt received his doctorate in Neuroscience from University College London (UCL). From 1980 he was a scientific staff member at the Lab of Molecular Biology in Cambridge but moved back to UCL in 1998 as Professor of Molecular Neuroscience. His research has been concentrated on the relationship between molecules and behaviour particularly around the neurobiology of pain, depression and addiction. Most recently he has been working with Professor Bazbek Davletov and Dr Maria Maiaru leveraging the neurotoxic properties of the botulinum toxin to specifically silence key pain-processing neurons. He was elected a fellow of the Academy of Medical Sciences in 2001.

    Tanja Ouimet

    Head of Clinical Operations, Pharmaleads
    Tanja Ouimet

    Tanja holds a PhD in Neurosciences from the University of Montréal. She then moved to Paris to pursue her research on metalloproteases as drug targets in academia before joining Pharmaleads in 2006 as Head of Biochemistry, characterizing metalloprotease and inhibitor activity in vitro and in vivo, through the design of specific assays. Her work was essential in selecting Pharmaleads’ drug candidates, Dual Enkephalinase Inhibitors (DENKI) for preclinical and clinical development in the treatment of severe pain.
    In 2014, Tanja was appointed Head of Clinical Operations overseeing all operational aspects of the DENKIs clinical trials. She was named Director of Clinical Development in 2017.
     

    Theo Meert

    Head of R&D Global Government Grant Office, Janssen Pharmaceutica N.V.
    Theo Meert

    Prof Theo F. Meert is head of the R&D Global Government Grant office (G3O) of J&J. He is also a professor and scientific advisor/researcher at different universities: Leuven, Antwerp, Hasselt and Ghent.
    During his career at J&J that started in 1981, Dr. Meert has been appointed to multiple international global functions. Within his various functions, he guided different multidisciplinary research teams, some with full development drugs, in the field of CNS, including pain.
    Dr. Meert’s scientific expertise is reflected in multiple patents (>15), publications (> 243), congress communications (> 200) and invited lectures (>190). Dr. Meert obtained a Ph.D. in psychopharmacology and a Ph.D. in Medicine/Anesthesiology
     

    Zahid Ali

    Head Clinical Pharmacology Translational Sciences, Mundipharma research Ltd
    Zahid Ali

    At Mundipharma research Zahid is part of the team that in-licenses and develops assets for pain and non- pain indications. During his industry career he has focused on translational medicine - initially at MSD followed by GSK and Pfizer where he has led multiple projects including pain related Nav1.7, Nav1.8 and P2X7. He has also extensively represented industry in precompetitive consortia including IMI Europain 1. Prior to his current role, Zahid was the CSO for a London based biotech Calchan Ltd which included a Cav2.2 blocker and ASK1 inhibitor in the portfolio which were being developed for pain and fibrosis.

    Official Media Partner

    Supporters

    VENUE

    Remote UK

    United Kingdom

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Pain Therapeutics 2020 Preliminary Attendees List

    Download

    Pain Therapeutics 2020 Brochure - UPDATED

    Download

    Two Day Programme 2020

    Download

    Speaker Interview with Stephen Hunt

    Download

    Past Attendees

    Download

    Co-Chair Invite Letter

    Download

    2020 Conference Speakers

    Download

    Pain Therapeutics Conference 2019 - Janssen

    Download

    Pain Therapeutics Conference 2019 - CHDR

    Download

    Pain Therapeutics Conference 2019 - Ensysce Biosciences

    Download

    Pain Therapeutics Conference 2019 - Pfizer

    Download

    Pain Therapeutics Conference 2019 - Lotus

    Download

    Pain Therapeutics Conference 2019 - Centrexion

    Download

    Media Partners


    Select Science

    Official Media Partner
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    The British Journal of Pain

    Official Media Partner
    http://bjp.sagepub.com/

    The British Journal of Pain is the official journal of the British Pain Society. It provides scientists and clinicians in pain medicine with peer-reviewed review articles and expert opinions on all aspects of pain management from basic science to its clinical application including pain physiology, pharmacology and interventions. This journal provides content of multidisciplinary interest and reviews and forecasts important issues and trends in the management of acute and chronic pain.


    Pain News

    Official Media Partner
    https://www.britishpainsociety.org/pain-news-1/

    The British Pain Society Newsletter Pain News is published quarterly and is edited by Dr Arasu Rayen. Members of the Society will receive a free copy and are encouraged to contribute to the content.


    ACNR

    Official Media Partner
    http://www.acnr.co.uk

    ACNR (Advances in Clinical Neuroscience & Rehabilitation) is one of the most widely read publications in the neurology field in the UK. It provides concise review articles, specialist reviews of core papers from international journals, conference news, book reviews, short accounts of best management practice, case reports, news of awards/appointments and more. This independently produced journal is available free of charge to members of the profession, and we welcome your input.

    Media Partners


    European Biotechnology Network

    Supporters
    http://european-biotechnology.net/

    The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe. The non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    Copybook - Pharmaceutical

    Supporters
    http://www.copybook.com/pharmaceutical

    Copybook is a global business network with many pharmaceutical events, exhibitions and seminars. We encourage business-to-business transactions and work tirelessly to gain our customers new business contracts worldwide. You can add events, companies and associations for free. When you are a member, you can add your company to the events listed in order to encourage other visitors to arrange meetings and appointments at those events to facilitate new business contracts. Want to see how we can increase your business network and transactions? SIGN UP FOR FREE today! Copybook – Your Global Business Network


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.


    Farmavita

    Supporters
    https://farmavitar.com

    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


    Genetic Engineering News

    Supporters
    http://www.genengnews.com

    Genetic Engineering & Biotechnology News (GEN) is the most authoritative and widely read biotechnology news publication in the world.Published 21 times a year,GEN's unique news and technology focus include the entire bioproduct life cycle from early-stage R&D to applied research and bioprocess through to commercialization. GEN is the only publication that provides the full range of the biotechnology market coverage in areas such as omics, drugs and biomarker discovery, bioprocessing, clinical research, molecular diagnostics and biobusiness. For a free subscription go to: http://www.genengnews.com/subscriptions.aspx


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Remote UK


    United Kingdom

    Remote UK

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out